Latest in Migraine & Headache

cantechletter.com
575 words

AbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant (QULIPTA®) in Head-to-Head Migraine Prevention Trial

MONTREAL, Oct. 29, 2026 /CNW/ — AbbVie (NYSE: ABBV) announced the publication of results from the Phase 3 TEMPLE study in The Lancet Neurology. The randomized, double-blind, head-to-head study… AbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant (QULIPTA®) in Head-to-Head Migraine Prevention…

Migraine & Headache

Migraine and headache disorders: CGRP drugs and other treatments, triggers and research.

  • 16 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.